EUVIMEDEUVIMED entdecken
Crossref

Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors

Lai Wei, Mengxing Tian, Qian Han, Wen Wang, Xin Jin, Xintian Xu

Clinical Nutrition ESPEN · 2026

DOI: 10.1016/j.clnesp.2026.103288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nutrition ESPEN, 2026. Verfasst von Lai Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chest Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Sarcopenia, Serum Albumin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: To explore the value of pretreatment myosteatosis and albumin-myosteatosis gauge (AMG) in predicting overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs). METHODS: This single-center, retrospective study included a total of 119 patients with lung cancer. Myosteatosis was assessed on pretreatment CT at L3 level by mean skeletal muscle density (SMD). AMG was calculated as SMD ∗ serum albumin. The time-dependent receiver operating characteristic curve was used to determine the optimal AMG score cut-off value. The predictive value of myosteatosis and AMG on overall survival was evaluated by the Kaplan-Meier method and Cox proportional hazard models. A nomogram was created based on AMG to predict OS. RESULTS: Patients with low AMG had shorter OS compared with patients with high AMG. (3-year survival rate: low AMG, 20.8% [95%CI: 8.4%-51.9%] versus high AMG, 68.2% [95%CI: 52.4%-88.7%]) No significate difference was observed in patients with and without myosteatosis. (HR = 1.46, 95%CI 0.77-2.76, P = 0.246) In the multivariable analysis, AMG remained a significant predictor of OS. (HR = 3.29, 95% CI 1.51-7.16, p = 0.003) The prediction model for OS based on the AMG was also created with C-index 0.78. A statistically significant but weak positive correlation was observed between myosteatosis and sarcopenia (Phi coefficient = 0.24, p < 0.05). CONCLUSION: AMG was a significant prognostic factor of OS in patients with lung cancer treated with ICIs. A weak correlation between myosteatosis and sarcopenia was observed in patients with lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmune Checkpoint InhibitorsSarcopeniaSerum AlbuminHumansFemaleMaleRetrospective StudiesAgedMiddle AgedProportional Hazards ModelsKaplan-Meier EstimateMuscle, SkeletalPrognosisPredictive Value of TestsROC CurveAged, 80 and over

Stichwörter der Autor:innen

Albumin-myosteatosis gaugeLung cancerMysteotosisOverall survival

Substanzen

Immune Checkpoint InhibitorsSerum Albumin

Autor:innen und Institutionen

  • Department of Chest Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Cancer Center, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
  • Department of Nutrition, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China. Electronic address: 13676986549@126.com.
  • Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: jinxinrd@alumni.hust.edu.cn.
  • Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: 595764747@qq.com.

Zitieren

APA

Wei, L., Tian, M., Han, Q., Wang, W., Jin, X., & Xu, X. (2026). Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2026.103288

Vancouver

Wei L, Tian M, Han Q, Wang W, Jin X, Xu X. Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors. Clinical Nutrition ESPEN. 2026. doi:10.1016/j.clnesp.2026.103288

BibTeX
@article{Wei2026,
  author = {Wei, Lai and Tian, Mengxing and Han, Qian and Wang, Wen and Jin, Xin and Xu, Xintian},
  title = {Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors},
  journal = {Clinical Nutrition ESPEN},
  year = {2026},
  doi = {10.1016/j.clnesp.2026.103288}
}
Kostenlos starten →